Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OncoMed Pharmaceuticals and Bayer HealthCare have widened their cancer stem cell collaboration, according to which Bayer has agreed to manufacture Wnt pathway biologic product candidate.
Subscribe to our email newsletter
Bayer will manufacture the bulk drug substance at its Berkeley, California clinical manufacturing center to support Phase 1 clinical testing planned to commence in 2012.
OncoMed Pharma president and CEO Paul Hastings said they continue to make progress in their Wnt pathway programs, and this manufacturing agreement underscores the commitment of both parties to collaboratively advance anti-cancer stem cell programs into development.
Last year, OncoMed and Bayer HealthCare had forged a broad strategic alliance valued at up to $387.5m per program, plus potential double-digit royalties, to develop cancer stem cell antibody and protein therapeutics targeting the Wnt signaling pathway.
The first program from the collaboration, antibody therapeutic product candidate OMP-18R5, is expected to enter clinical testing in 2011.
Under the collaboration, Bayer has the option to license OncoMed’s biologics in the Wnt pathway at any point through the completion of Phase 1 studies.
Bayer and OncoMed are also working together to discover small molecule Wnt signaling inhibitors as part of the collaboration.